{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:06:39Z","timestamp":1785863199171,"version":"3.56.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Mirvetuximab soravtansine is an antibody-drug conjugate targeting FR\u03b1, which has not only shown antitumor activity and tolerability in ovarian carcinoma with FR\u03b1 high expression, but has also been incorporated into NCCN guidelines to treat patients with platinum-resistant disease. Sequential cases were retrieved from a previously published cohort of gynecologic pathology cases in which FOLR1 immunohistochemistry had been performed at our institution. Clinical and pathologic data collected included patients\u2019 age, tumor histotype, tumor grade (if reported or relevant to histotype), primary tumor site, FIGO stage, and type of specimen. FOLR1 immunohistochemical results were collected from the report, including the overall tumor percentage and intensity reported, and subsequently determined if this was an overall positive or negative result (positivity defined as per current recommendations for therapy eligibility, 75%, 2\u20133+ intensity). The FOLR1 immunohistochemical slide was reviewed by 2 gynecologic pathologists and jointly recorded the following parameters: percent of cells staining at each level of intensity (0\u20133), range of staining intensity (0\u20133), percent of cells with membranous, cytoplasmic, or mixed staining, apical-only versus any membranous staining, percent of cells with complete membranous staining, and presence of abrupt transition (0 \u2013 no staining at all, juxtaposed to 2\u20133+ staining). One hundred twenty cases were reviewed and scored, 119 of which had original reported scores available for comparison. The staining intensity record was 0 in 9 (7.5%) of the cases, 0\u20131 in 3 (2.5%), 0\u20132 in 11 (9.2%), 0\u20133 in 88 (73.3%), 1\u20133 in 3 (2.5%), 2\u20133 in 4 (3.3%), and 3 in 2 (1.7%). The percent of positive cells at 2\u20133+ intensity as per quartile of cases was 12 (10.0%) cases with 0%, 14 (11.7%) cases with 1%\u201324%, 15 (12.5%) with 25%\u201349%, 28 (23.3%) with 50%\u201374%, and 51 (42.5%) with \u226575%. Using the original clinical reports, 67 (56.3%) of 119 cases were positive; 55 (67.9%) of 81 resection cases were positive, while 12 (31.6%) of 38 biopsy cases were positive. On re-review, 51 (42.5%) of all 120 cases were positive, with 41 (50%) of 82 resection cases being positive and 10 (26.3%) of 38 biopsy cases being positive. Overall, 18 (15.1%) of 119 cases had a clinically significant change (i.e. positive to negative or negative to positive). When broken down by type of specimen, 16 (19.8%) of 81 resection cases had a significant change, while only 2 (5.3%) of 38 biopsy cases had a significant change. Of the original scores taken from the report, the score was clearly stated in 117 reports, of which 47 cases were reported within 65% to 85% 2\u20133+ intensity. Seventeen of these 47 on rescoring were changed significantly as to a clinical action outcome; all 17 of these were changed from \u201cpositive\u201d to \u201cnegative.\u201d The 18th case, which was changed on rescoring, was the singular case that was changed from \u201cnegative\u201d to \u201cpositive,\u201d which was originally reported at 60% and on review was scored 75%. On rescoring of all 120 cases, 32 cases were 65% to 85% 2\u20133+ intensity. The heterogeneous staining pattern of FR\u03b1 expression may lead to difficulties in scoring and interpretation, which can have an impact on clinical management.<\/jats:p>","DOI":"10.1097\/pgp.0000000000001210","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:05:43Z","timestamp":1785859543000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Folate Receptor Immunohistochemical Staining Heterogeneity in Gynecologic Cancers"],"prefix":"10.1097","author":[{"given":"Barrett C.","family":"Lawson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Malpica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"R1-20260804","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN Guidelines\u00ae Insights: ovarian cancer\/fallopian tube cancer\/primary peritoneal cancer, version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"R2-20260804","doi-asserted-by":"crossref","first-page":"m3773","DOI":"10.1136\/bmj.m3773","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"BMJ"},{"key":"R3-20260804","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"R4-20260804","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R6-20260804","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/PGP.0000000000001140","article-title":"Heterogeneity and scoring reproducibility of folate receptor 1 immunohistochemistry in high-grade serous carcinoma","volume":"45","author":"Liang","year":"2026","journal-title":"Int J Gynecol Pathol"},{"key":"R7-20260804","doi-asserted-by":"crossref","first-page":"156359","DOI":"10.1016\/j.prp.2026.156359","article-title":"Performance of the VENTANA FOLR1 assay for folate receptor alpha: real-world evidence from 313 Chinese participants","volume":"279","author":"Chen","year":"2026","journal-title":"Pathol Res Pract"},{"key":"R8-20260804","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ygyno.2024.06.008","article-title":"Folate receptor alpha expression in low-grade serous ovarian cancer: exploring new therapeutic possibilities","volume":"188","author":"Manning-Geist","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R9-20260804","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ygyno.2024.11.010","article-title":"Analysis of real world FR\u03b1 testing in ovarian, fallopian tube, and primary peritoneal cancers","volume":"192","author":"Previs","year":"2025","journal-title":"Gynecol Oncol"},{"key":"R10-20260804","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/PGP.0000000000001053","article-title":"Folate receptor immunohistochemical staining and gynecologic tumors: initial experience with 216 cases","volume":"44","author":"Lawson","year":"2025","journal-title":"Int J Gynecol Pathol"},{"key":"R11-20260804","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2024.09.021","article-title":"Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma","volume":"191","author":"Rushton","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R12-20260804","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.3390\/ijms26115222","article-title":"Folate receptor alpha in advanced epithelial ovarian cancer: diagnostic role and therapeutic implications of a clinically validated biomarker","volume":"26","author":"Zannoni","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R13-20260804","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R14-20260804","doi-asserted-by":"crossref","first-page":"17442","DOI":"10.18632\/oncotarget.7856","article-title":"Concordance of folate receptor-\u03b1 expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients","volume":"7","author":"Boogerd","year":"2016","journal-title":"Oncotarget"},{"issue":"6A","key":"R15-20260804","first-page":"3567","article-title":"Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue","volume":"28","author":"Markert","year":"2008","journal-title":"Anticancer Res"},{"key":"R16-20260804","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","article-title":"Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes","volume":"128","author":"Bax","year":"2023","journal-title":"Br J Cancer"},{"key":"R17-20260804","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1002\/ctm2.454","article-title":"Folate receptor \u03b1 increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer","volume":"11","author":"Sakai","year":"2021","journal-title":"Clin Transl Med"},{"key":"R18-20260804","doi-asserted-by":"crossref","first-page":"121802","DOI":"10.1016\/j.lfs.2023.121802","article-title":"Recent advances in using folate receptor 1 (FOLR1) for cancer diagnosis and treatment, with an emphasis on cancers that affect women","volume":"326","author":"Varaganti","year":"2023","journal-title":"Life Sci"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PGP.0000000000001210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:05:45Z","timestamp":1785859545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PGP.0000000000001210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000001210","relation":{},"ISSN":["0277-1691","1538-7151"],"issn-type":[{"value":"0277-1691","type":"print"},{"value":"1538-7151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}